CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Mesenchymal stem cell-derived exosomes enriched with miR-218 reduce the epithelial-mesenchymal transition and angiogenesis in triple-negative breast cancer cells.
Mesenchymal stem cell-derived exosomes enriched with miR-218 reduce the epithelial-mesenchymal transition and angiogenesis in triple-negative breast cancer cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
这些发现表明,ADMSC 外泌体可有效恢复乳腺癌细胞中的 miR-218 水平,且 miR-218 可通过同时靶向血管生成和 EMT 来阻止乳腺癌进展。
上皮-间质转化(EMT)和血管生成是参与肿瘤侵袭与转移的形态发生过程。微小RNA(miRNA)异常表达与这些过程有关。外泌体被认为是癌症治疗中递送miRNA的潜在天然载体。miR-218是一种肿瘤抑制性miRNA,其表达下调与EMT和血管生成相关。本研究旨在利用脂肪来源间充质干细胞外泌体(ADMSC-exosome)向乳腺癌细胞递送miR-218,并在体外评估miR-218的肿瘤抑制作用。
从ADMSC条件培养液中分离外泌体,通过电穿孔将miR-218装载入外泌体。采用qPCR检测MDA-MB-231乳腺癌细胞中靶基因Runx2和Rictor的mRNA表达。通过细胞活力、凋亡和Boyden小室实验,考察含miR-218外泌体对乳腺癌细胞的影响;采用体外成管实验评估处理后MDA-MB-231细胞的血管生成能力。
miR-218模拟物可高效装载至ADMSC外泌体并递送到MDA-MB-231细胞。暴露于含miR-218外泌体后,MDA-MB-231细胞中miR-218靶基因Runx2和Rictor显著降低;上皮标志物CDH1表达增加,间质标志物CDH2表达下降。通过含miR-218外泌体恢复miR-218,可降低乳腺癌细胞活力、运动能力、侵袭性和血管生成能力。
这些发现提示,ADMSC外泌体可有效恢复乳腺癌细胞中的miR-218水平;miR-218同时靶向血管生成和EMT,可能阻止乳腺癌进展。
The epithelial-mesenchymal transition (EMT) and angiogenesis are morphogenetic processes implicated in tumor invasion and metastasis. It is found that the aberrant expression of microRNAs (miRNAs) contributes to these processes. Exosomes are considered potential natural vehicles for miRNA delivery in cancer therapy. miR-218 is one of the tumor suppressor miRNAs and its downregulation is associated with EMT and angiogenesis. We aimed to use adipose mesenchymal stem cells-derived exosomes (ADMSC-exosomes) for miR-218 delivery to breast cancer cells and evaluate miR-218 tumor-suppressing properties in vitro.
Exosomes were isolated from conditioned media of ADMSCs. miR-218 was loaded to exosomes using electroporation. mRNA expression of target genes (Runx2 and Rictor) in MDA-MB-231 breast cancer cells was evaluated by qPCR. To explore the effects of miR-218 containing exosomes on breast cancer cells, viability, apoptosis, and Boyden chamber assays were performed. The angiogenic capacity of MDA-MB-231 cells after treatment with miR-218 containing exosomes was assessed by in vitro tube formation assay.
miR-218 mimic was efficiently loaded to ADMSC-exosomes and delivered to MDA-MB-231 cells. Exposure to miR-218 containing exosomes significantly decreased miR-218 target genes (Runx2 and Rictor) in MDA-MB-231 cells. They increased the expression of epithelial marker (CDH1) and reduced mesenchymal marker (CDH2). miR-218 restoration using miR-218 containing exosomes reduced viability, motility, invasion, and angiogenic capacity of breast cancer cells.
These findings suggest that ADMSC-exosomes can efficiently restore miR-218 levels in breast cancer cells and miR-218 can prevent breast cancer progression with simultaneous targeting of angiogenesis and EMT.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。